CFTR and cystic fibrosis: Ultimately, a drug that interferes with the activity of key regulatory elements—such as regulatory microRNAs and transcription factors—which translate the action of host defense modifier genes into CFTR-mediated residual function or ENaC activity will be an attractive instrument to counterbalance the susceptibility of CF patients to infection and inflammation.